Mifegyne (Mifepristone)

Mifepristone binds to progesterone receptors in the uterine lining, blocking the hormone’s action. This causes the decidua to break down and the gestational sac to detach, while also making the uterus more responsive to prostaglandins, which trigger uterine contractions needed for expulsion.

The specific dose of Mifegyne is determined by the prescribing clinician based on the patient’s clinical situation, gestational age, and local medical guidelines. Healthcare professionals select the appropriate tablet strength and regimen at the point of care.

Mifegyne is intended for use in early pregnancy termination and is not used to treat ongoing pregnancy. It is contraindicated in ongoing pregnancy beyond the approved gestational limit and should not be used while breastfeeding, as safety data are insufficient.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mifegyne (mifepristone) is the most widely used oral abortifacient for early pregnancy termination and is typically followed by misoprostol. Compared with surgical methods, it offers a non‑invasive alternative, and compared with other medical regimens, it provides higher efficacy when used within the approved gestational window.

Mifegyne tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Mifegyne is taken orally as a single tablet dose under medical supervision. After ingestion, a prostaglandin analogue such as misoprostol is usually prescribed 24–48 hours later to complete the termination process. Administration is performed in a clinical setting with appropriate follow‑up.

Serious risks include heavy hemorrhage, severe infection, incomplete abortion requiring surgical intervention, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of excessive bleeding, fever, or severe abdominal pain and seek immediate medical attention if these occur.

Mifegyne should not be used by individuals with chronic adrenal insufficiency, those on long‑term corticosteroid therapy, patients with known hypersensitivity to mifepristone, or anyone with a confirmed intrauterine pregnancy beyond nine weeks gestation. Contraindications also include certain bleeding disorders and concurrent use of specific interacting medications.